Combination therapies with Cbl-b inhibitor compounds
The present disclosure relates to combination therapies with Cbl-b inhibitor compounds, and compositions and kits comprising combinations with the Cbl-b compounds. Also provided are methods of using the combinations with Cbl-b compounds and compositions thereof, such as in therapeutic methods.
1. A method of treating colon cancer or colorectal cancer or breast cancer in a subject in need thereof, comprising administering to the subject
(a) 0.1 mg to 50 mg of a Cbl-b inhibitor compound of the following formula;
and
(b) one or more checkpoint inhibitors selected from a group consisting of anti-PD-1 antibodies, anti-CTLA4 antibodies or LAG3 antibodies.
2. The method of claim 1 wherein the anti-PD1 antibody is Pembrolizumab.
3. The method of claim 1 wherein the anti-PD1 antibody is nivolumab.
4. The method of claim 1 wherein the anti-PD1 antibody is cemiplimab.